DUBLIN--(BUSINESS WIRE)--The "Cyclin Dependent Kinase 7 - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Cell division protein kinase 7 is an enzyme that in humans is encoded by the CDK7 gene.
Scope
- The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 7
- The report reviews Cyclin Dependent Kinase 7 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin Dependent Kinase 7 targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin Dependent Kinase 7 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cyclin Dependent Kinase 7 targeted therapeutics
Companies Featured
- Aurigene Discovery Technologies Ltd.
- Beta Pharma Inc.
- Cyclacel Pharmaceuticals Inc.
- Qurient Co. Ltd.
- Syros Pharmaceuticals Inc.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/qdb3pm/cyclin_dependent?w=4
